

Special Issue

Obesity and Diabetes: Genetic Markers and Pharmacological Interventions

Message from the Guest Editors

Obesity and diabetes mellitus prevalence has been rising rapidly over the last few decades. Novel pharmacological agents targeting both diabetes mellitus and its complications have redirected medical interventions towards a patient-centered method of treatment. However, in an extremely heterogenous group of diabetic patients, patient-tailored treatment protocols still remain challenging. Precision medicine refers to the opportunity to provide the right therapy for the right patient at the right time. Recently, advances in medical science, biology, genetics, basic research and technology have made the implementation of precision medicine more attractive and affordable at the same time. In this Special Issue, we will try to present existing evidence about genetic markers that have been associated with obesity, diabetes mellitus and diabetes complication predisposition, diagnosis, and treatment. We will also try to collect and analyze primary research data on the efficacy of newer antidiabetic agents based on genetic markers to shed light on the future of precision medicine in diabetes and obesity.

Guest Editors

Dr. Kalliopi Kotsa

Dr. Theocharis Koufakis

Dr. Maria Grammatiki

Deadline for manuscript submissions

closed (25 February 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/91762

*Journal of Personalized
Medicine*

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).